Evercore ISI Group Maintains In-Line on Editas Medicine, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group has maintained an In-Line rating on Editas Medicine but has significantly lowered its price target from $7 to $3, indicating a bearish outlook.
October 23, 2024 | 3:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Evercore ISI Group has maintained an In-Line rating on Editas Medicine but has significantly lowered its price target from $7 to $3, indicating a bearish outlook.
The significant reduction in the price target from $7 to $3 by Evercore ISI Group suggests a negative outlook on Editas Medicine's future performance. This is likely to put downward pressure on the stock price in the short term as investors react to the lowered expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100